ArticleRespiratory medicine case reports2025
Erythrocytosis as an indicator of disease progression of small cell lung cancer: A case report.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case involves a 62-year-old male diagnosed with extensive-stage small cell lung cancer (ES-SCLC) originating from the right lower lobe with brain metastases. The patient underwent stereotactic radiosurgery (SRS) and received four cycles of combination therapy with cisplatin, etoposide, and durvalumab, followed by maintenance therapy with durvalumab to achieve disease control. On day 156 after treatment initiation, hemoglobin (Hb) levels increased to 16.9 g/dL, indicating polycythemia. Concurrently, new brain metastatic lesions were identified, and serum erythropoietin (EPO) levels were markedly elevated at 406 mIU/mL. Whole-brain radiation therapy (WBRT) was initiated, resulting in a subsequent reduction in hemoglobin levels and improvement in polycythemia. This report describes a rare case of secondary polycythemia associated with ES-SCLC. Notably, WBRT appeared to contribute to the normalization of serum EPO levels and resolution of polycythemia. This report elucidates the clinical course and relevance of this condition based on a literature review.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.